目的 评价康艾注射液辅助化学疗法（化疗）对直肠癌术后临床疗效、生活质量及其不良反应的影响。 方法 2010年4月－2011年2月收治的50例直肠癌术后化疗患者，随机分为试验组与对照组，每组25例。两组均采用FOLFOX方案化疗，在化疗同时，试验组予静脉滴注康艾注射液辅助治疗。连续治疗6个周期，比较两组临床疗效、生活质量及其不良反应情况。 结果 试验组治疗有效率为84%，对照组为88%，差异无统计学意义（P＞0.05）；两组生活质量改善率差异无统计学意义（P＞0.05）；试验组胃肠道反应、白细胞计数下降发生率低于对照组，差异有统计学意义（P＜0.05）。 结论 康艾注射液用于直肠癌术后的辅助化疗可降低化疗的不良反应。
Background Tongxinluo capsule is a new drug for cardio- cerebral vascular diseases on the national essential drug list of China, and the second-class award of National Science and Technology Development of China, 2001. Objective This review aims to assess the effect (harms and benefits) of Tongxinluo capsule for unstable angina. Search strategy electronic searchs The Cochrane Heart Review Group specialised trials register,The Cochrane Controlled Trials Register, published in the latest issue of the Cochrane Library, MEDLINE, EMBASE, CBM, Chinese Cochrane Centre Controlled Trials Register, Current Controlled Trials (www. controlled-trials. com), The National Research Register Handsearchs We will search 83 journals of Chinese traditional medicine. Inclusion riteria We will include randomised controlled trials of Tonxinluo capsule versus placebo or other current phamarcotherapy or other Chinese medicinal herbs in the participants with unstable angina pectoris. Studies will report mortality (sudden death from acute myocardial infarction), severity of angina pectoris, frequency of acute attack angina, ECG improvement, rate of dosage reducing or taking frequency of nitroglycerine and symptom improvement, etc. Data analysis Data will be included in a meta-analysis if they are available, of sufficient quality and sufficiently similar.